Preclinical pharmacokinetics, pharmacodynamics and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates (vol 148, pg 1116, 2006)

被引：0
|
作者：
Kelley, S. K.
Gelzleichter, T.
Xie, D.
Lee, W. P.
Darbonne, W. C.
Qureshi, F.
Kissler, K.
Oflazoglu, E.
Grewal, I. S.
机构：
来源：
BRITISH JOURNAL OF PHARMACOLOGY | 2007年 / 150卷 / 02期
关键词：
D O I：
10.1038/sj.bjp.0707129
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：248 / 248
页数：1
相关论文
共 40 条
  • [1] Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates
    Kelley, Sean K.
    Gelzleichter, Thomas
    Xie, Dong
    Lee, Wyne P.
    Darbonne, Walter C.
    Qureshi, Ferhan
    Kissler, Kim
    Oflazoglu, Ezogelin
    Grewal, Iqbal S.
    BRITISH JOURNAL OF PHARMACOLOGY, 2006, 148 (08) : 1116 - 1123
  • [2] Preclinical pharmacokinetics and pharmacodynamics of SGN-40, a humanized anti-CD40 antibody.
    Miller, DM
    Kelley, S
    Gelzleichter, T
    Grewal, L
    Darbonne, WC
    BLOOD, 2003, 102 (11) : 689A - 689A
  • [3] Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40
    Law, CL
    Gordon, KA
    Collier, J
    Klussman, K
    McEarchern, JA
    Cerveny, CG
    Mixan, BJ
    Lee, WP
    Lin, ZH
    Valdez, P
    Wahl, AF
    Grewal, IS
    CANCER RESEARCH, 2005, 65 (18) : 8331 - 8338
  • [4] Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40 (vol 65, pg 8331, 2005)
    Law, CL
    Gordon, KA
    Collier, J
    Klussman, K
    McEarchern, JA
    Cerveny, CG
    Mixan, BJ
    Lee, WP
    Lin, Z
    Valdez, P
    Wahl, AF
    Grewal, IS
    CANCER RESEARCH, 2006, 66 (04) : 2495 - 2495
  • [5] Preclinical antitumor activity of a humanized anti-CD40 monoclonal antibody SGN-40.
    Law, CL
    Lee, WP
    Lin, ZH
    Grewal, IS
    Wahl, A
    BLOOD, 2003, 102 (11) : 646A - 646A
  • [6] Preclinical Analysis of the Combined Activity of SGN-40, Anti-CD40 Monoclonal Antibody, with Rituximab in Non-Hodgkin Lymphoma
    Lewis, Timothy S.
    McCormick, Renee S.
    McEarchern, Julie A.
    Kissler, Kim
    Stone, Ivan J.
    Gerber, Hans-Peter
    Drachman, Jonathan G.
    Grewal, Iqbal
    Law, Che-Leung
    BLOOD, 2008, 112 (11) : 561 - 562
  • [7] A phase I humanized Anti-CD40 monoclonal antibody (SGN-40) in patients with multiple myeloma.
    Hussein, MA
    Berenson, JR
    Niesvizky, R
    Munshi, NC
    Harrop, KL
    McDonald, M
    Drachman, JG
    BLOOD, 2005, 106 (11) : 723A - 723A
  • [8] Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: Clinical implications
    Tai, YT
    Catley, LP
    Mitsiades, CS
    Burger, R
    Podar, K
    Shringpaure, R
    Hideshima, T
    Chauhan, D
    Hamasaki, M
    Ishitsuka, K
    Richardson, P
    Treon, SP
    Munshi, NC
    Anderson, KC
    CANCER RESEARCH, 2004, 64 (08) : 2846 - 2852
  • [9] Phase I trial of a humanized anti-CD40 monoclonal antibody (SGN-40) in the treatment of multiple myeloma.
    Hussein, MA
    Berenson, JR
    Niesvizky, R
    Munshi, NC
    Anderson, KC
    Ryan, KL
    Baumgartner, KT
    Miller, DM
    Drachman, JG
    McDonald, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 580S - 580S
  • [10] The humanized anti-CD40 monoclonal antibody, SGN-40, signals apoptosis in non-Hodgkin's lymphoma by dual mechanisms.
    McCormick, Renee S.
    Lewis, Timothy S.
    Miyamoto, Jamie
    Sutherland, May S. K.
    Drachman, Jonathan G.
    Grewal, Iqbal S.
    Law, Che-Leung
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3451S - 3452S
1234